Richter's Transformation clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.